Acta Clin Belg

• Latest
• Best
• Search…

• Acta Clin Belg · Feb 2015

  Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.

  We evaluated azacitidine (Vidaza(®)) safety and efficacy in patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML), in a real-life setting. Treatment response, dose, and schedule were assessed. ⋯ Our data support previous findings that azacitidine has a clinically acceptable safety profile and shows efficacy.

  explore further… or not…